Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Frequently asked questions
What sector does Human Metabolome Technologies Inc (6090) operate in?
Human Metabolome Technologies Inc belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Human Metabolome Technologies Inc (6090) current stock price?
As of the latest data, Human Metabolome Technologies Inc stock price is ¥603, with a previous close of ¥600. Human Metabolome Technologies Inc gained ¥3 in the last trading session, representing a 0.5% increase.
What is Human Metabolome Technologies Inc (6090) current market capitalization?
Human Metabolome Technologies Inc market cap is approximately 3.27 billion.
What is Human Metabolome Technologies Inc (6090) Earnings Per Share (EPS)?
The trailing EPS is ¥36.
What is Human Metabolome Technologies Inc (6090) Price-to-Earnings (P/E) ratio?
Human Metabolome Technologies Inc current P/E ratio is 16.92.
What is Human Metabolome Technologies Inc (6090) EBITDA?
Human Metabolome Technologies Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 29.39 million.
Does Human Metabolome Technologies Inc (6090) pay dividends?
Yes. Human Metabolome Technologies Inc pays annual dividends with an annualized yield of 2.99% and an estimated annual payout of ¥18 per share.
When is the next ex-dividend date for Human Metabolome Technologies Inc (6090)?
The next ex-dividend date is scheduled for June 29, 2027.
What is Human Metabolome Technologies Inc (6090) beta (volatility) score?
Human Metabolome Technologies Inc has a beta of 1.496, suggesting it is more volatile than the market.
